THE ROLE OF STAPHYLOCOCCUS AUREUS IN THE CLINICAL DIAGNOSIS OF DIABETIC PATIENTS

Publications

Share / Export Citation / Email / Print / Text size:

Postępy Mikrobiologii - Advancements of Microbiology

Polish Society of Microbiologists

Subject: Microbiology

GET ALERTS

ISSN: 0079-4252
eISSN: 2545-3149

DESCRIPTION

0
Reader(s)
0
Visit(s)
0
Comment(s)
0
Share(s)

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue / page

Related articles

VOLUME 57 , ISSUE 2 (September 2018) > List of articles

THE ROLE OF STAPHYLOCOCCUS AUREUS IN THE CLINICAL DIAGNOSIS OF DIABETIC PATIENTS

Renata Barbara Klekotka / Elżbieta Mizgała-Izworska * / Witold Drzastwa2, Bogdan Mazur

Keywords : diabetic patients, Staphylococcus aureus

Citation Information : Postępy Mikrobiologii - Advancements of Microbiology. Volume 57, Issue 2, Pages 166-178, DOI: https://doi.org/10.21307/PM-2018.57.2.166

License : (CC BY-NC-ND 4.0)

Published Online: 20-May-2019

ARTICLE

ABSTRACT

Discovering interactions between the etiology of the infection and diabetic patients’ immune system activity may be essential for the relevant clinical diagnosis. The dynamics of colonization of the nasal vestibule by Staphylococcus aureus and the development of the prevention strategies against infection are different for various populations. Moreover, the colonization of the nasal vestibule might involve both molecular and epidemiological ctorsfa. Researchers have reported that the identification of methicillin-resistant strains S. aureus (MRSA) with similar molecular characteristics allows to assess the ability of the microorganism to spread and the risk of infection in diabetic patients. Knowledge of these characteristics allows to take precautions in patients exposed to S. aureus. S. aureus is an ethiological factors of many severe diseases both in people with weakened immune system and in healthy individuals. Usually, excess weight and obesity contribute to the incidence of diabetes mellitus type 2 (DM2). However, the colonization by S. aureus is a probable risk factor for infection. Among S. aureus virulence factors, superantigens (SAgs) are essential for pathogenicity. The long-term effect of the superantigen toxic shock syndrome toxin-1 (TSST-1) might be glucose intolerance. This toxin also induces systemic inflammation as a result of the increased exotoxin concentration in blood, and, therefore, may be the causative factor of diabetes. Chronic exposure to staphylococcal superantigens may contribute to the development of diabetes, suggesting a need to conduct targeted therapies against S. aureus superantigens.

Content not available PDF Share

FIGURES & TABLES

REFERENCES

1. Alizargar J., Sharif M.R., Sharif A.: Risk factors of methicillin-resistant Staphylococcus aureus colonization in diabetic outpatients, a prospective cohort study. Int. J. Microbiol. Res. 4, 147–151 (2013)

2. Alonzo F., Torres V.J.: The bicomponent pore-forming leucocidins of Staphylococcus aureus. Microbiol. Mol. Biol. Rev. 78, 199–230 (2014)

3. Badaru A., Pihoker C.: Type 2 diabetes in childhood: clinical characteristics and role of β-cell autoimmunity. Curr. Diab. Rep. 12, 75–81 (2012)

4. Burian M., Grumann D., Holtfreter S., Wolz C., Goerke C., Bröker B.M.: Expression of staphylococcal superantigens during nasal colonization is not sufficient to induce a systemic neutralizing antibody response in humans. Eur. J. Clin. Microbiol. Infect. Dis. 31, 251–256 (2012)

5. Casqueiro J., Casqueiro J., Alves C.: Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J. Endocrinol. Metab. 16, 27–36 (2012)

6. Cervantes-García E., García-Gonzalez R., Reyes-Torres A., Resendiz-Albor A.A., Salazar-Schettino P.M.: Staphylococcus aureus small colony variants in diabetic foot infections. Diabet. Foot Ankle, 6, 26431 (2015)

7. Dai X., Zhan J., Demmy T.A., Poordad F.B., Fauceglia P.L., Zhang H., Wu L.: Monocytes play different roles in stimulating T cells in obese diabetic individuals. Int. J. Immunopathol. Pharmacol. 28, 374–383 (2015)

8. De Bus L., Coessens G., Boelens J., Claeys G., Decruyenaere J., Depuydt P.: Microbial etiology and antimicrobial resistance in healthcare-associated versus community-acquired and hospital-acquired bloodstream infection in a tertiary care hospital. Diagn. Microbiol. Infect. Dis. 77, 341–345 (2013)

9. DeFuria J., Belkina A.C., Jagannathan-Bogdan M., Snyder-Cappione J., Carr J.D., Nersesova Y.R., Markham D., Strissel K.J., Watkins A.A., Zhu M., Allen J., Bouchard J., Toraldo G., Jasuja R., Obin M.S., McDonnell M.E., Apovian C., Denis G.V., Nikolajczyk B.S.: B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile. Proc. Natl. Acad. Sci. USA, 110, 5133–5138 (2013)

10. Dumont A.L., Nygaard T.K., Watkins R.L., Smith A., Kozhaya L., Kreiswirth B.N., Shopsin B., Unutmaz D., Voyich J.M., Torres V.J.: Characterization of a new cytotoxin that contributes to Staphylococcus aureus pathogenesis. Mol. Microbiol. 79, 814–825 (2011)

11. Fast D.J., Schlievert P.M., Nelson R.D.: Nonpurulent response to toxic shock syndrome toxin 1-producing Staphylococcus aureus. Relationship to toxin-stimulated production of tumor Necrosis factor. J. Immunol. 140, 949–853 (1988)

12. Fijałkowski K., Czernomysy-Furowicz G., Ferlas M.: Staphylococcus aureus versus the immune system. Post. Mikrobiol. 47, 497–501 (2008)

13. Frasca D., Ferracci F., Diaz A., Romero M., Lechner S., Blomberg B.B.: Obesity decreases B cell responses in young and elderly individuals. Obesity (Silver Spring), 24 615–625 (2016)

14. Fraser J.D., Proft T.: The bacterial superantigen and superantigen-like proteins. Immunol. Rev. 225, 226–243 (2008)

15. Gillet Y., Etienne J. i wsp.: Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet, 359, 753–759 (2002)

16. Gravet, A., Colin D.A., Keller D., Girardot R., Monteil H., Prévost G.: Characterization of a novel structural member, LukE-LukD, of the bi-component staphylococcal leucotoxins family. FEBS Lett. 436, 202–208 (1998)

17. Guha M., Bai W., Nadler J.L., Natarajan R.: Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. J. Biol. Chem. 275, 17728–17739 (2000)

18. Hernandez C., Cobos-Trigueros N., Feher C., Morata L., De La Calle C., Marco F., Almela M., Soriano A., Mensa J., Del Rio A., Martinez J.A.: Community-onset bacteraemia of unknown origin: clinical characteristics, epidemiology and outcome. Eur. J. Clin. Microbiol. Infect. Dis. 33, 1973–1980 (2014)

19. Holtfreter S., Bauer K., Thomas D., Feig C., Lorenz V., Roschack K., Friebe E., Selleng K., Lövenich S., Greve T., Greinacher A., Panzig B., Engelmann S., Lina G., Bröker B.M.: egc-Encoded superantigens from Staphylococcus aureus are neutralized by human sera much less efficiently than are classical staphylococcal enterotoxins or toxic shock syndrome toxin. Infect. Immun. 72, 4061–4071 (2004)

20. Huseby M.J., Kruse A.C., Digre J., Kohler P.L., Vocke J.A., Mann E.E., Bayles K.W., Bohach G.A., Schlievert P.M., Ohlendorf D.H., Earhart C.A.: Beta toxin catalyzes formation of nucleoprotein matrix in staphylococcal biofilms. Proc. Natl. Acad. Sci. USA, 107, 14407–14412 (2010)

21. Klein E., Smith D.L., Laxminarayan R.: Hospitalizations and deaths caused by methicillin- resistant Staphylococcus aureus, United States, 1999–2005. Emerg. Infect. Dis. 13, (2007)

22. Klekotka R.B., Mizgała E., Król W.: The etiology of lower respiratory tract infections in people with diabetes. Pneumonol. Alergol. Pol. 83, 401–408 (2015)

23. Kluytmans J., van Belkum A., Verbrugh H.: Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin. Microbiol. Rev. 10, 505–520 (1997)

24. Kulhankova K., King J., Salgado-Pabón W.: Staphylococcal toxic shock syndrome: superantigen-mediated enhancement of endotoxin shock and adaptive immune suppression. Immunol. Res. 59, 182–187 (2014)

25. Kübler A., Jaeschke R., Jankowski M.: Sepsis and septic shock. In Szczeklik A. (ed), Internal Diseases. The state of knowledge on year 2010. Practical Medicine, Kraków, s. 2200–2205 (2010)

26. Laupland K.B., Gregson D.B., Zygun D.A., Doig C.J., Mortis G., Church D.L.: Severe bloodstream infections: a population-based assessment. Crit. Care Med. 32, 992–997 (2004)

27. Lee P.K., Deringer J.R., Kreiswirth B.N., Novick R.P., Schlievert P.M.: Fluid replacement protection of rabbits challenged subcutaneous with toxic shock syndrome toxins. Infect. Immun. 59, 879–884 (1991)

28. Lipsky B.A., Pecoraro R.E., Chen M.S., Koepsell T.D.: Factors affecting staphylococcal colonization among NIDDM outpatients. Diabetes Care, 10, 483–486 (1987)

29. Lipsky B.A., Tabak Y.P., Johannes R.S., Vo L., Hyde L., Weigelt J.A.: Skin and soft tissue infections in hospitalized patients with diabetes: Culture isolates and risk factors associated with mortality, length of stay and cost. Diabetologia, 53, 914–923 (2010)

30. Lydyard P.M., Whelan A., Fanger M.W.: Short lectures. Immunology, Scientific Publishing PWN SA, Warszawa, s. 97–103 (2008)

31. Małecki R., Rosiński K., Adamiec R.: Etiological factors of infections in diabetic foot syndrome – attempt to define optimal empirical therapy. Adv. Clin. Exp. Med. 23, 39–48 (2014)

32. McKane C.K., Marmarelis M., Mendu M.L., Moromizato T., Gibbons F.K., Christopher K.B.: Diabetes mellitus and community-acquired bloodstream infections in the critically ill. J. Crit. Care. 29, 70–76 (2014)

33. Miro J.M., Fowler V.G. i wsp.: Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin. Infect. Dis. 41, 507–514 (2005)

34. Mueller E.A., Merriman J.A., Schlievert P.M.: Toxic Shock Syndrome Toxin-1, Not Alpha Toxin, Mediated Bundaberg Fatalities. Microbiology, 161, 2361–2368 (2015)

35. Muñoz P., Hortal J., Giannella M., Barrio J.M., Rodríguez-Créixems M., Pérez M.J., Rincón C., Bouza E.: Nasal carriage of S. aureus increases the risk of surgical site infection after major heart surgery. J. Hosp. Infect. 68, 25–31 (2008)

36. Naber C.K.: Staphylococcus aureus Bacteremia: Epidemiology, pathophysiology, and management strategies. Clin. Infect. Dis. 48, 231–237 (2009)

37. Nada H.A., Gomaab N.I.M., Elakhrasa A., Wasfya R., Bakera A.: Skin colonization by superantigen-producing Staphylococcus aureus in Egyptian patients with atopic dermatitis and its relation to disease severity and serum interleukin-4 level. Int. J. Infect. Dis. 16, 29–33 (2012)

38. Nienaber J.J., Sharma Kuinkel B.K., Clarke-Pearson M., Lamlertthon S., Park L., Rude T.H., Barriere S., Woods C.W., Chu V.H., Marín M., Bukovski S., Garcia P., Corey G.R., Korman T., Doco-Lecompte T., Murdoch D.R., Reller L.B, Fowler V.G.: Methicillin-susceptible Staphylococcus aureus endocarditis isolates are associated with clonal complex 30 genotype and a distinct repertoire of enterotoxins and adhesins. J. Infect. Dis. 204, 704–713 (2011)

39. Olokoba A.B., Obateru O.A., Olokoba L.B.: Type 2 diabetes mellitus: a review of current trends. Oman Med. J. 27, 269–273 (2012)

40. Panton P.N., Valentine F.C.O.: Staphylococcal toxin. Lancet, 219, 506–508 (1932)

41. Petrovici C.G., Dorobăt C., Bejan C., Juganariu G., Simiraş E., Filip O., Luca V., Miftode E.: Epidemiology and clinical features in diabetic patients with invasive infections treated at the Clinical Hospital of Infectious Diseases of laşi, Romania, between 2008–2010. Rev. Med. Chir. Soc. Med. Nat. Iasi. 115, 1035–1041 (2011)

42. Petrovici C.G., Leca D., Teodor A., Dorneanu O., Juganariu G., Dorobăt C., Egidia M.: Bacterial meningitis during sepsis in diabetic patient. Rev. Med. Chir. Soc. Med. Nat. Iasi. 117, 901–907 (2013)

43. Piya M.K., McTernan P.G., Kumar S.: Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin. J. Endocrinol. 216, T1-T15 (2013)

44. Poindexter N.J., Schlievert P.M.: Suppression of immunoglobulin-secreting cells from human peripheral blood by toxic-shock-syndrome toxin-1. J. Infect. Dis. 153, 772–779 (1986)

45. Pragman A.A., Schlievert P.M.: Virulence regulation in Staphylococcus aureus: the need for in vivo analysis of virulence factor regulation. FEMS Immunol. Med. Microbiol. 42, 147–154 (2004)

46. Price C.L., Al Hassi H.O., English N.R., Blakemore A.I., Stagg A.J., Knight S.C.: Methylglyoxal modulates immune responses: relevance to diabetes. J. Cell. Mol. Med. 14, 1806–1815 (2010)

47. Przyjałkowski W.: Central nervous system infections. In Szczeklik A. (ed), Internal Diseases. The state of knowledge on year 2010, Practical Medicine, Kraków, s. 2149–2171 (2010)

48. Rodríguez E.A., Correa M.M., Ospina S., Atehortúa S.L., Jiménez J.N.: Differences in epidemiological and molecular characteristics of nasal colonization with Staphylococcus aureus (MSSA-MRSA) in children from a university hospital and day care centers. Plos One, 9, e101417 (2014)

49. Roliński J., Sacha T., Immunosuppression. In Szczeklik A. (ed), Internal Diseases. The state of knowledge on year 2010, Practical Medicine, Kraków, s. 1599–1608 (2010)

50. Salgado-Pabón W., Breshears L., Spaulding A.R., Merriman J.A., Stach C.S., Horswill A.R., Peterson M.L., Schlievert P.M.: Superantigens are critical for Staphylococcus aureus Infective endocarditis, sepsis, and acute kidney injury. M. bio. 4, 00494–00513 (2013)

51. Salgado-Pabón W., Schlievert P.M.: Models matter: the search for an effective Staphylococcus aureus vaccine. Nat. Rev. Microbiol. 12, 585–591 (2014)

52. Shah B.R., Huh J.E.: Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care, 26, 510–513 (2003)

53. Shallcross L.J., Fragaszy E., Johnson A.M., Hayward AC.: The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis. Lancet Infect. Dis. 13, 43–54 (2013)

54. Shambat M., Haggar S., Vandenesch A., Lina F., van Wamel G., Arakere W.J., Swensson G., Norrby-Teglund M.A.: Levels of alpha-toxin correlate with distinct phenotypic response profiles of blood mononuclear cells and with agr background of community-associated Staphylococcus aureus isolates. Plos One, 9, e106107 (2014)

55. Sieradzki J.: Diabetes mellitus and metabolic syndrome. In Szczeklik A. (ed), Internal Diseases. The state of knowledge on year 2010, Practical Medicine, Kraków, , s. 1243–1284 (2010)

56. Sollid J.U., Furberg A.S., Hanssen A.M., Johannessen M.: Staphylococcus aureus: determinants of human carriage. Infect. Genet. Evol. 21, 531–41 (2014)

57. Spaan A.N., Schiepers A., de Haas C.J., van Hooijdonk D.D., Badiou C., Contamin H., Vandenesch F., Lina G., Gerard NP., Gerard C., van Kessel K.P., Henry T., van Strijp J.A.: Differential Interaction of the Staphylococcal Toxins Panton-Valentine Leukocidin and γ-Hemolysin CB with Human C5a Receptors. J. Immunol. 195, 1034–1043 (2015).

58. Spaulding A.R., Salgado-Pabón W., Kohler P.L., Horswill A.R., Leung D.Y., Schlievert P.M.: Staphylococcal and streptococcal superantigen exotoxins. Clin. Microbiol. Rev. 26, 422–447 (2013)

59. Spaulding A.R., Satterwhite E.A., Lin Y.C., Chuang-Smith O.N., Frank K.L., Merriman J.A., Schaefers M.M., Yarwood J.M., Peterson M.L., Schlievert P.M.: Comparison of Staphylococcus aureus strains for ability to cause infective endocarditis and lethal sepsis in rabbits. Front. Cell. Infect. Microbiol. 2, 18 (2012)

60. Stoeckle M., Kaech C., Trampuz A., Zimmerli W.: The role of diabetes mellitus in patients with bloodstream infections. Swiss Med. Wkly. 138, 512–529 (2008)

61. van Belkum A., Verkaik N.J., de Vogel C.P., Boelens H.A., Verveer J., Nouwen J.L., Verbrugh H.A., Wertheim H.F.L.: Reclassification of Staphylococcus aureus nasal carriage types. J. Infect. Dis. 15, 199,1820–1826 (2009)

62. Vandenesch F., Naimi T., Enright M.C., Lina G., Nimmo G.R., Heffernan H., Liassine N., Bes M., Greenland T., Reverdy M.E., Etienne J.: Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg. Infect. Dis. 9, 978–984 (2003)

63. Voyich J.M., Braughton K.R., Sturdevant D.E., Whitney A.R., Saïd-Salim B., Porcella S.F., Long R.D., Dorward D.W., Gardner D.J., Kreiswirth B.N., Musser JM., DeLeo F.R.: Insights into mechanisms used by Staphylococcus aureus to avoid destruction by human neutrophils. J. Immunol. 175, 3907–3919 (2005)

64. Vu B.G., Gourronc F.A., Bernlohr D.A., Schlievert P.M., Klingelhutz A.J.: Staphylococcal superantigens stimulate immortalized human adipocytes to produce chemokines. Plos One, 8, e77988 (2013)

65. Vu B.G., Stach C.S., Kulhankova K., Salgado-Pabón W., Klingelhutz A.J, Schlievert PM.: Chronic superantigen exposure induces systemic inflammation, elevated bloodstream endotoxin, and abnormal glucose tolerance in rabbits: possible role in diabetes. M. Bio. 24, e02554 (2015)

66. Vu B.G., Stach C.S., Salgado-Pabón W., Diekema D.J., Gardner S.E., Schlievert P.M.: Superantigens of Staphylococcus aureus from patients with diabetic foot ulcers. J. Infect. Dis. 210, 1920–1927 (2014)

67. Wertheim H.F., Melles D.C., Vos M.C., van Leeuwen W., van Belkum A., Verbrugh H.A., Nouwen J.L.: The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect. Dis. 5, 751–762 (2005)

68. Xiong Y.Q., Willard J., Yeaman M.R., Cheung A.L., Bayer A.S.: Regulation of Staphylococcus aureus alpha-toxin gene (hla) expression by agr, sarA, and sae in vitro and in experimental infective endocarditis. J. Infect. Dis. 194, 1267–1275 (2006)

69. Yazdanpanah L., Nasiri M., Adarvishi S.: Literature review on the management of diabetic foot ulcer. World J. Diabetes. 15, 37–53 (2015)

70. Zhai X., Qian G., Wang Y., Chen X., Lu J., Zhang Y., Huang Q., Wang Q.: Elevated B Cell Activation is Associated with Type 2 Diabetes Development in Obese Subjects. Cell. Physiol. Biochem. 38, 1257–1266 (2016)

EXTRA FILES

COMMENTS